Japan Tissue Engineering Co

Japan Tissue Engineering Co Accounts Payable

The Accounts Payable of Japan Tissue Engineering Co (7774.T) as of Nov 20, 2026 is 106.90 M JPY. In the previous year, Accounts Payable was 109.28 M JPY — a change of -2.18% (lower).

Accounts Payable

106.90 MJPY

YoY

-2.18%

Last updated:

Accounts Payable of Japan Tissue Engineering Co is 2026 106.90 M JPY. Accounts Payable of Japan Tissue Engineering Co was 2025 109.28 M JPY. It decreases by -2.18% lower compared to the previous year.

The Japan Tissue Engineering Co Accounts Payable history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Accounts Payable
Date
Accounts Payable
Jan 1, 2019
90.42 M JPY
Jan 1, 2020
119.81 M JPY
Jan 1, 2021
147.47 M JPY
Jan 1, 2022
117.09 M JPY
Jan 1, 2023
67.71 M JPY
Jan 1, 2024
83.59 M JPY
Jan 1, 2025
109.28 M JPY
Jan 1, 2026
106.90 M JPY
The Japan Tissue Engineering Co Accounts Payable history
YEARAccounts PayableYoY
106.90 MJPY-2.18%
109.28 MJPY+30.74%
83.59 MJPY+23.45%
67.71 MJPY-42.17%
117.09 MJPY-20.60%
147.47 MJPY+23.09%
119.81 MJPY+32.51%
90.42 MJPY+22.45%
73.84 MJPY+51.16%
48.85 MJPY-13.36%
56.38 MJPY+42.93%
39.45 MJPY-62.01%
103.83 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Japan Tissue Engineering Co Stock analysis

What does Japan Tissue Engineering Co do? Japan Tissue Engineering Co., Ltd. generates revenue through three business segments. The Regenerative Medicine Product segment sells autologous cultured epidermis JACE and autologous cultured cartilage JACK to medical institutions. The Regenerative Medicine Outsourcing segment offers CDMO, CRO, consulting, and contract manufacturing services for cell processed products. The Research and Development Support segment sells human cultured tissues developed using the company's advanced culture technology. Medical institutions purchase regenerative medicine products, while pharmaceutical and biotech companies utilize outsourcing services for cell-based therapies. The company's products are sold to healthcare providers and research-focused clients across Japan and potentially internationally. The Regenerative Medicine Product segment focuses on selling JACE and JACK, which are used in medical treatments requiring tissue regeneration. These products are specifically designed for autologous use, meaning they are derived from the patient's own cells. The Outsourcing segment provides specialized services to support the development and manufacturing of cell-based therapies, targeting pharmaceutical and biotech firms. The Research and Development Support segment supplies tissues for research applications, leveraging the company's internal technology to meet client needs in scientific development. JACE and JACK are key products in the Regenerative Medicine Product segment, directly sold to medical institutions for clinical use. The Outsourcing segment serves as a service provider for cell therapy development, offering CDMO and CRO capabilities. The Research and Development Support segment's human cultured tissues are marketed to research organizations seeking advanced cell culture solutions. All segments contribute to the company's revenue by addressing specific needs in regenerative medicine and cell therapy development. Japan Tissue Engineering Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Japan Tissue Engineering Co stock

Accounts Payable of Japan Tissue Engineering Co is 106.90 M JPY in 2026.

Accounts Payable of Japan Tissue Engineering Co changed from 109.28 M JPY to 106.90 M JPY, representing a -2.18% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Accounts Payable Japan Tissue Engineering Co since 2006 – with annual values, charts, and detailed analysis.

Accounts payable represents money owed to suppliers for goods and services received. It is a key component of working capital management.

Accounts Payable's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Payable's Japan Tissue Engineering Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Japan Tissue Engineering Co

All Key Metrics — Japan Tissue Engineering Co